Promoting myelin repair and return of function in multiple sclerosis.

Promoting myelin repair and return of function in multiple sclerosis.
复制标题

DOI:
10.1016/j.febslet.2011.08.017
复制
发表时间:
2011-12-01
期刊:
影响因子:
3.5
通讯作者:
John GR
John GR
中科院分区:
生物学3区
文献类型:
--
作者:
Zhang J;Kramer EG;Asp L;Dutta DJ;Navrazhina K;Pham T;Mariani JN;Argaw AT;Melendez-Vasquez CV;John GR

文献摘要

参考文献

被引文献

相似文献

多发性硬化症(MS)是一种中枢神经系统炎症性脱髓鞘疾病。脱髓鞘轴突的传导阻滞是早期神经症状的基础,但轴突横断和神经元丢失被认为是造成更永久性慢性缺陷的原因。有几种疗法被批准用于治疗复发-缓解型多发性硬化症,所有这些疗法都是免疫调节的,临床证明可以降低病变形成和恶化的几率。然而,现有的方法在预防MS患者残疾发作方面仅部分有效,而保护产生髓磷脂的少突胶质细胞和增强髓磷脂修复的新疗法可能改善长期预后。在转基因小鼠体内的研究有助于表征MS患者神经病理学产生的机制,并确定了少突胶质细胞保护和髓鞘修复的潜在途径。然而,尚未批准直接针对这些区域的治疗方法,此外,疾病病变中脱髓鞘和轴突横断之间的关系仍不清楚。在这里,我们回顾了针对自身免疫性脱髓鞘模型中少突胶质细胞保护和髓磷脂修复的转化研究,以及它们作为治疗多发性硬化症患者的潜在相关性。
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS. Conduction block in demyelinated axons underlies early neurological symptoms, but axonal transection and neuronal loss are believed to be responsible for more permanent chronic deficits. Several therapies are approved for treatment of relapsing-remitting MS, all of which are immunoregulatory and clinically proven to reduce the rate of lesion formation and exacerbation. However, existing approaches are only partially effective in preventing the onset of disability in MS patients, and novel treatments to protect myelin-producing oligodendrocytes and enhance myelin repair may improve long-term outcomes. Studies in vivo in genetically modified mice have assisted in the characterization of mechanisms underlying the generation of neuropathology in MS patients, and have identified potential avenues for oligodendrocyte protection and myelin repair. However, no treatments are yet approved that target these areas directly, and in addition, the relationship between demyelination and axonal transection in the lesions of the disease remain unclear. Here, we review translational research targeting oligodendrocyte protection and myelin repair in models of autoimmune demyelination, and their potential relevance as therapies in MS patients.
DOI: 10.1016/j.neuron.2008.06.028
发表时间: 2008-08-28
期刊: NEURON
影响因子: 16.2
作者:
Brinkmann, Bastian G.;Agarwal, Amit;Sereda, Michael W.;Garratt, Alistair N.;Mueller, Thomas;Wende, Hagen;Stassart, Ruth M.;Nawaz, Schanila;Humml, Christian;Velanac, Viktorija;Radyushkin, Konstantin;Goebbels, Sandra;Fischer, Tobias M.;Franklin, Robin J.;Lai, Cary;Ehrenreich, Hannelore;Birchmeier, Carmen;Schwab, Markus H.;Nave, Klaus Armin
通讯作者: Nave, Klaus Armin
DOI: 10.1038/367371a0
发表时间: 1994-01-27
期刊: NATURE
影响因子: 64.8
作者:
BARRES, BA;RAFF, MC;BARDE, YA
通讯作者: BARDE, YA
DOI: 10.1016/s0896-6273(00)80155-5
发表时间: 1996-08-01
期刊: NEURON
影响因子: 16.2
作者:
Canoll, PD;Musacchio, JM;Salzer, JL
通讯作者: Salzer, JL
DOI: 10.1056/nejmoa010994
发表时间: 2002-01-17
影响因子: 158.5
作者:
Chang, A;Tourtellotte, WW;Trapp, BD
通讯作者: Trapp, BD
DOI: 10.4049/jimmunol.165.5.2535
发表时间: 2000-09-01
影响因子: 4.4
作者:
Anhuf, D;Weissenbach, M;Schaper, F
通讯作者: Schaper, F